606 results on '"Soliman, Pamela T."'
Search Results
102. EFFORT: EFFicacy Of adavosertib in parp ResisTance: A randomized two-arm non-comparative phase II study of adavosertib with or without olaparib in women with PARP-resistant ovarian cancer.
103. Phase 1b dose expansion and translational analyses of olaparib in combination with the oral AKT inhibitor capivasertib in recurrent endometrial, triple negative breast, and ovarian, primary peritoneal, or fallopian tube cancer
104. Endometrial biomarkers in premenopausal women with obesity: an at-risk cohort
105. Contributors
106. Neoplastic Diseases of the Uterus
107. Endometrial Cancer Associated with Defective DNA Mismatch Repair
108. Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the Pten heterozygote murine model
109. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome
110. Correction: Hu, W., et al. Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype. Cancers 2020, 12, 2436
111. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer
112. When to Operate, Hesitate and Reintegrate: Society of Gynecologic Oncology Surgical Considerations During the COVID-19 Pandemic
113. The role of mucoregulatory agents after continence-preserving urinary diversion surgery
114. Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma
115. Laparoscopic Extraperitoneal Para-Aortic Lymphadenectomy in Locally Advanced Cervical Cancer#: A Prospective Correlation of Surgical Findings With Positron Emission Tomography/Computed Tomography Findings
116. Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer
117. Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype
118. Abstract CT163: Temsirolimus in combinaton with metformin in patients with advanced or refractory endometrial cancers
119. A prospective multicenter international single-arm observational study on the oncological safety of the sentinel lymph node algorithm in stage I intermediate-risk endometrial cancer (SELECT, SEntinel Lymph node Endometrial Cancer Trial)
120. Present-day management of uterine leiomyosarcoma: Evaluation of treatment sequencing and other prognostic factors.
121. Pathogenesis and Clinical Management of Uterine Serous Carcinoma
122. Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study
123. Systematic Approach to Selecting and Preparing a Medical Power of Attorney in the Gynecologic Oncology Center
124. Pelvic fractures after radiotherapy for cervical cancer: Implications for Survivors
125. Association between adiponectin, insulin resistance, and endometrial cancer
126. Women With Synchronous Primary Cancers of the Endometrium and Ovary: Do They Have Lynch Syndrome?
127. Risk Factors for Young Premenopausal Women With Endometrial Cancer
128. Mechanisms of cervical cancer
129. Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases
130. Her-2/neu Overexpression and Amplification in Uterine Papillary Serous Carcinoma
131. Abstract 2070: Exploration of markers of synergistic lethality of PARP and PI3K-Akt-mTOR inhibitors in women's cancers
132. Abstract CT020: Phase I dose escalation of olaparib (PARP inhibitor) and selumetinib (MEK Inhibitor) combination in solid tumors with Ras pathway alterations
133. Preoperative PET/CT does not accurately detect extrauterine disease in patients with newly diagnosed high‐risk endometrial cancer: A prospective study
134. A comparison of adjuvant therapy approaches for patients with early-stage uterine serous carcinoma.
135. Correlation of surgeon radiology assessment with laparoscopic scoring in patients with advanced-stage ovarian cancer.
136. Bevacizumab beyond progression: Impact of subsequent bevacizumab retreatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression.
137. Hypomagnesemia and Survival in Patients with Ovarian Cancer Who Received Chemotherapy with Carboplatin
138. A systematic process to enhance selection of a prepared medical decision maker.
139. 32 - Neoplastic Diseases of the Uterus: Endometrial Hyperplasia, Endometrial Carcinoma, Sarcoma: Diagnosis and Management
140. A prospective multicenter international singlearm observational study on the oncological safety of the sentinel lymph node algorithm in stage I intermediate-risk endometrial cancer (SELECT, SEntinel Lymph node Endometrial Cancer Trial).
141. Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy
142. Race and nodal disease status are prognostic factors in patients with stage IVB cervical cancer
143. Phase I trial of olaparib (PARP inhibitor) and vistusertib (mTORC1/2 inhibitor) in recurrent endometrial, ovarian and triple negative breast cancer.
144. The influence of surgeon volume on outcomes after pelvic exenteration for a gynecologic cancer
145. Selecting a prepared medical decision maker.
146. Adjuvant Therapy for Grade 3, Deeply Invasive Endometrioid Adenocarcinoma of the Uterus
147. Risk of Subsequent Ovarian Cancer After Ovarian Conservation in Young Women With Stage I Endometrioid Endometrial Cancer
148. Should We Perform Routine Peritoneal and Staging Biopsies at the Time of Risk-reducing Bilateral Salpingo-ophrectomy?
149. Postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer: The ENGOT-EN2/DGCG trial.
150. Cancer Genomics and Important Oncologic Mutations: A Contemporary Guide for Body Imagers
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.